At Tactogen, we are developing a next generation of mental wellness medicines. Psychedelics and other transformative medicines have great promise to heal souls and change lives. Unfortunately, our complex and expensive medical system may keep these benefits out of reach for all but the wealthy. We're working to build a better system. Tactogen is a public benefit corporation whose goal is to make transformative medicines safer, more effective, and more accessible.

Co-founder & CeO

Matthew is a neuroscientist and data scientist with over thirty years of experience studying psychedelics. He started Tactogen to ensure the next generation of psychedelic medicines are safe, effective, and accessible to all. Matthew concentrates on IP, product roadmap, regulatory strategy, and scientific community-building.

Co-founder & COO

Luke believes that robust mental health is a planetary priority, and while therapy is helpful, it’s like digging a ditch with a teaspoon compared to psychedelics and talk therapy combined. That’s why he joined Matt to help commercialize safe, legal medicines that increase the connection between people. He concentrates on fundraising and grants, cash flow, corporate development, community partnerships, marketing, ops, team-building, and culture.

Developing IP That Provides Unique Value to Patients

Tactogen is a mission-based and research-driven pharmatech company that uses machine learning and targeted assays to identify promising medicines and new treatments. We seek to understand and leverage the ability of novel small molecules to improve health in a variety of contexts, including anxiety, depression, and stress-related disorders.

July 25, 2022

DEA WITHDRAWS PLAN TO BAN FIVE TRYPTAMINES

On Friday, facing opposition from Tactogen and a coalition of scientists and other companies, the DEA announced they were withdrawing their proposal to ban five tryptamines. 

February 14, 2022

Tactogen opposes ban of five tryptamines

Tactogen, in collaboration with Mindstate Design Labs, has formally filed our opposition to a federal proposal to ban five tryptamine derivatives. These compounds do not present significant public health risks. On the contrary, they present significant opportunities to advance science and medicine.

August 5, 2021

Tactogen in conversation with the community

Tactogen CEO Matthew Baggott, Ph.D. had the opportunity to sit down with journalist Erica Rex to discuss our approach to psychedelic medicine. You can read it here. This follows an appearance Matthew made earlier on the Drug Positive podcast of DanceSafe founder Emanuel Sferios.